Find latest Hepatocellular Cancer videos
·
200+ videos
Video Player is loading.
10 seconds
Playback speed
Intermediate HCC Panel Discussion: Treatment Options and Strategies
In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.
Key topics include:
• An overview of the available treatment options for this heterogeneous patient population with intermediate HCC
• A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT
• Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments
• The importance of the multidisciplinary care team for the treatment of intermediate HCC
Key clinical takeaways:
• Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice
• Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies
• Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches
• Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety
• Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists
This is the full video. Get the shorter highlights video here: https://www.youtube.com/watch?v=bgRYdAvnw9U&t=0s
Prefer to listen to this on the go? Get the audio version of this podcast on your favorite platform: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-treatment/?media=1
Follow us on social media:
LinkedIn
X
This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This video is developed by cor2ed.com
Published January 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Key topics include:
• An overview of the available treatment options for this heterogeneous patient population with intermediate HCC
• A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT
• Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments
• The importance of the multidisciplinary care team for the treatment of intermediate HCC
Key clinical takeaways:
• Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice
• Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies
• Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches
• Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety
• Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists
This is the full video. Get the shorter highlights video here: https://www.youtube.com/watch?v=bgRYdAvnw9U&t=0s
Prefer to listen to this on the go? Get the audio version of this podcast on your favorite platform: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-treatment/?media=1
Follow us on social media:
X
This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This video is developed by cor2ed.com
Published January 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Comments 0
Login to view comments.
Click here to Login
